Document is current

Article History

Received: 8 September 2025

Accepted: 9 January 2026

First Online: 19 February 2026

Competing interests

: C.E.A.S. receives fellowship grant support from the Alzheimer’s Association International Research Grant Program (25AARF-1411192). A.C.R. receives funding from the National Institute of Mental Health (MH129799), National Institute on Aging (AG066515) and the Mental Illness Research, Education, and Clinical Centers/Department of Veterans Affairs. M.M.M. has served on scientific advisory boards and/or has consulted for Althira, Biogen, Cognito Therapeutics, Eisai, LabCorp, Lilly, Merck, Novo Nordisk, Roche, Siemens Healthineers; received honorariums speaking from Novo Nordisk, PeerView Institute, and Roche; and receives grant support from the NIH, Department of Defense, Alzheimer’s Association, and Davos Alzheimer’s Collaborative. S.E.S. has served scientific advisory boards on biomarker testing and clinical care pathways for Eisai and Novo Nordisk and has received speaking fees for presentations on biomarker testing from Eisai, Eli Lilly, and Novo Nordisk. J.J.A. receives funding from the NIH, Alzheimer’s Association, and the Alzheimer’s Disease Data Initiative, she serves on the Executive Committee for the National Centralized Repository for Alzheimer’s disease and Related Dementias (NCRAD) and is a member of the Medial Advisory Council for the Association for Frontotemporal Degeneration.